GlassScriptPhysician profile
Nancy D Sellars
NPI 1770003097
$937.81
in general payments reported to CMS, 2019-2025
14 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $22.62 · 2023: $262 · 2024: $112 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $170.64 | 2021-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Gilead Sciences, INC. | $156.36 | 2021-2025 | Biktarvy |
| Abbvie INC. | $120.60 | 2021 | |
| Kerecis Limited | $108.26 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Merck Sharp & Dohme LLC | $84.54 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $71.19 | 2021 | |
| Amgen INC. | $47.94 | 2023 | Amjevita, Avsola, Enbrel |
| Smith+Nephew, INC. | $41.39 | 2022-2024 | Collagenase Santyl |
| Janssen Biotech, INC. | $35.92 | 2023 | Symtuza |
| Grifols USA, LLC | $23.37 | 2024 | Xembify |
| Csl Behring | $22.34 | 2023 | Hizentra |
| Viiv Healthcare Company | $21.37 | 2023 | Rukobia |
| Glaxosmithkline, LLC. | $20.12 | 2021 | |
| Aurinia Pharma U.S., INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Sellars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.